<DOC>
	<DOCNO>NCT00073879</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fludarabine cyclophosphamide , use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy . Sometimes transplanted cell reject body 's normal tissue . Alemtuzumab tacrolimus may prevent happen . PURPOSE : Phase II trial study effectiveness combine fludarabine cyclophosphamide alemtuzumab treat patient undergo allogeneic stem cell transplantation recurrent metastatic renal cell carcinoma ( kidney cancer ) .</brief_summary>
	<brief_title>Fludarabine , Cyclophosphamide , Alemtuzumab Treating Patients With Recurrent Metastatic Renal Cell Carcinoma ( Kidney Cancer ) Undergoing Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety feasibility fludarabine , cyclophosphamide , alemtuzumab patient recurrent metastatic renal cell carcinoma undergo HLA-matched allogeneic stem cell transplantation . OUTLINE : This pilot , multicenter study . - Conditioning : Patients receive fludarabine IV 30 minute day -6 -2 , cyclophosphamide IV 2 hour day -6 -5 , alemtuzumab IV day -4 -2 . - Allogeneic transplantation : Allogeneic stem cell infuse day 0 . Patients receive graft-vs-host disease prophylaxis tacrolimus IV orally approximately 30 day . Patients follow weekly 100 day 6 , 12 , 18 , 24 , 36 , 48 , 60 month transplantation . PROJECTED ACCRUAL : A total 20 patient ( 10 HLA-identical related donor 10 match unrelated donor ) accrue study .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis recurrent metastatic renal cell carcinoma Failed interleukin2 ( IL2 ) base therapy OR intolerant IL2 Clinically evident followable disease Availability 1 follow compatible donor : Related HLAidentical 1Ag mismatch donor Unrelated HLAA , B , DRB1matched donor PATIENT CHARACTERISTICS : Age Any age Performance status Karnofsky 70100 % Life expectancy No concurrent illness severely limit life expectancy Hematopoietic Not specify Hepatic No episode hepatitis within past month No evidence chronic active hepatitis cirrhosis Renal Creatinine great 2 mg/dL Cardiovascular LVEF least 40 % No uncontrolled arrhythmias No symptomatic cardiac disease Pulmonary FEV_1 , FVC , DLCO least 50 % predict ( unless due metastatic disease ) Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No active infection HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>